What is Podofilox Gel 0.5% used for?

Podofilox Gel 0.5% is indicated for Genital warts, Cervical intraepithelial neoplasia.

Who makes Podofilox Gel 0.5%?

Podofilox Gel 0.5% is developed by Dermax SA.

What development phase is Podofilox Gel 0.5% in?

Podofilox Gel 0.5% is in Phase 3.

What are the side effects of Podofilox Gel 0.5%?

Common side effects include Local irritation, Pain, Bleeding.

Last reviewed 2026-04-23 · How we verify

Podofilox Gel 0.5%

Dermax SA · Phase 3 active Small molecule

Podofilox is a plant-derived antimitotic agent that inhibits cell division.

Podofilox is a plant-derived antimitotic agent that inhibits cell division. Used for Genital warts, Cervical intraepithelial neoplasia.

At a glance

Generic name	Podofilox Gel 0.5%
Sponsor	Dermax SA
Drug class	Antimitotic agent
Target	Tubulin
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

Podofilox works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division. This leads to cell cycle arrest and ultimately, cell death. Podofilox has been shown to be effective in treating certain types of cancer and genital warts.

Approved indications

Genital warts
Cervical intraepithelial neoplasia

Common side effects

Local irritation
Pain
Bleeding

Key clinical trials

Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Podofilox Gel 0.5% CI brief — competitive landscape report
Podofilox Gel 0.5% updates RSS · CI watch RSS
Dermax SA portfolio CI